All In Biotech

Drug Trial Radar · NCT05090891

To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

98

Planned (sponsor's estimate)

Start

May 5, 2022

Primary completion

Jul 30, 2027

Study completion Jan 20, 2033

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Oct 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagnosis of fibrodysplasia ossificans progressiva (FOP).

Conditions

  • Fibrodysplasia Ossificans Progressiva (FOP)

Interventions

  • INCB000928Drug

    INCBG000928 will be administered QD orally.

  • PlaceboDrug

    Placebo will be administered QD orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Double Blind Period: Occurrence of new heterotopic ossification (HO) lesions from baselineTime frame: Week 24

Locations

24 sites in 17 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • Children'S Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Penn Medicine - Perelman Center For Advanced Medicine

    Philadelphia, Pennsylvania · Active not recruiting

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina · Active not recruiting

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia · Completed

  • Murdoch Children'S Research Institute

    Parkville, Victoria, Australia · Active not recruiting

  • Albert Einstein Israelite Hospital

    São Paulo, Brazil · Active not recruiting

  • University Health Network Toronto General Hospital

    Toronto, Ontario, Canada · Active not recruiting

  • Centro de Estudios Reumatologicos

    Santiago, Chile · Active not recruiting

  • Beijing Childrens Hospital Capital Medical University

    Beijing, China · Recruiting

  • Tongji Hospital of Tongji University

    Shanghai, China · Recruiting

  • Shanghai Childrens Medical Center

    Shanghai, China · Recruiting

  • Childrens Hospital of Fudan University

    Shanghai, China · Recruiting

  • Ap-Hp Hopital Lariboisiere

    Paris, France · Recruiting

  • Hopital Necker-Enfants Malades

    Paris, France · Recruiting

  • Uniklinik Koln

    Cologne, Germany · Recruiting

  • Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore

    Rome, Italy · Active not recruiting

  • Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra

    Tlalpan, Mexico · Active not recruiting

  • Amsterdam Umc - Vu Medisch Centrum (Vumc)

    Amsterdam, Netherlands · Recruiting

  • Starship Childrens Hospital

    Auckland, New Zealand · Active not recruiting

  • Groote Schuur Hospital Radiation Oncology

    Cape Town, South Africa · Active not recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Active not recruiting

  • Hospital Universitario Ramon Y Cajal

    Madrid, Spain · Recruiting

  • Royal National Orthopaedic Hospital

    Stanmore, United Kingdom · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.